IL9 and neoplasm: Further analysis revealed a 12-fold increase in the proportion of tumor-infiltrated CD103+ DCs in the B16F10-IL9+BMDM group, which is a crucial driver of intratumoral CD8+ T-cell activation and antitumor immunity induction (27).